Keywords: Takeda, gpr40, TAK-875,diabetes,ema,peginesatide, anaemia, Dollow

Takeda's GPR40 agonist for diabetes promising in Ph II trial

Article | 28 February 2012

Print This

TAK-875 is currently in phase III trials in the US, Europe, Japan and Latin America, and is claimed to be ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in